読み込み中
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
通常取引
$3.284
+$0.014 · +0.43%
日中の時刻はETです。市場データは遅延する場合があります。
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
日中レンジ
現在 $3.284
52週レンジ
現在 $3.284
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
82
大幅な割安
センチメント
45
まちまち
リスク
50
やや高いリスク
モメンタム
29
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
日中レンジ
現在 $3.284
52週レンジ
現在 $3.284
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 4.07億 USD | 3.34億 USD | 1.24億 USD | 5215.8万 USD | 1009.7万 USD |
| 売上原価 | 4259.6万 USD | 5055.6万 USD | 1779.5万 USD | 411.7万 USD | 100万 USD |
| 粗利益 | 3.65億 USD | 2.83億 USD | 1.07億 USD | 4804.1万 USD | 909.7万 USD |
| 研究開発 | 6846.8万 USD | 5231.7万 USD | 3553.6万 USD | 3520.1万 USD | 9114万 USD |
| 販売・一般管理 | 3.37億 USD | 2.59億 USD | 1.34億 USD | 7659.9万 USD | 7230.3万 USD |
| 営業費用 | 4.06億 USD | 3.11億 USD | 1.7億 USD | 1.12億 USD | 1.63億 USD |
| 支払利息 | 2839.8万 USD | 2009.4万 USD | 887.4万 USD | 507.3万 USD | 450.2万 USD |
| 減価償却費と償却費 | 305.9万 USD | 206.3万 USD | 129.2万 USD | 114.4万 USD | 280.7万 USD |
| 営業利益 | −4097.7万 USD | −2795万 USD | −6327.6万 USD | −6375.9万 USD | −1.54億 USD |
| 純利益 | −6159.9万 USD | −3913.6万 USD | −6606.7万 USD | −6720.7万 USD | −1.58億 USD |
会社概要が更新されました 2026年10月9日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$13.00
上昇余地（295.86%）AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
